** Shares of drugmaker AbbVie ABBV.N rise 2.7% to $185.3 premarket
** AbbVie raises its 2025 profit forecast after better-than-expected sales of its newer immunology drugs Skyrizi and Rinvoq help it beat quarterly earnings expectations
** Company expects its annual adjusted profit to be between $12.09 and $12.29 per share, up from its previous estimate of $11.99 to $12.19
** ABBV earns adj. Q1 profit of $2.46 per share, compared with analysts' average expectation of $2.38
** As of last close, ABBV had risen 1.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。